Surmodics (NASDAQ:SRDX) Issues FY 2025 Earnings Guidance

Key Points

• Surmodics updated its FY 2025 earnings guidance, expecting earnings per share (EPS) of -0.350 to -0.200 and revenue of $116.5 million to $118.5 million, surpassing consensus estimates.
• The stock opened at $35.01 and has a market cap of $500.64 million, reflecting a P/E ratio of -25.19.
• Institutional investors and hedge funds hold 96.63% of Surmodics' stock, with a recent purchase of 4,000 shares by Strs Ohio valued at approximately $122,000.

Surmodics (NASDAQ:SRDX - Get Free Report) updated its FY 2025 earnings guidance on Friday. The company provided earnings per share (EPS) guidance of -0.350--0.200 for the period, compared to the consensus estimate of -0.546. The company issued revenue guidance of $116.5 million-$118.5 million, compared to the consensus revenue estimate of $115.7 million.

Surmodics Trading Down 0.1%

Surmodics stock opened at $35.01 on Friday. The company's fifty day simple moving average is $31.14 and its 200-day simple moving average is $30.88. The company has a quick ratio of 3.99, a current ratio of 5.14 and a debt-to-equity ratio of 0.27. Surmodics has a 12 month low of $26.00 and a 12 month high of $41.30. The stock has a market cap of $500.64 million, a P/E ratio of -25.19 and a beta of 1.31.

Analyst Upgrades and Downgrades

Separately, Needham & Company LLC restated a "hold" rating on shares of Surmodics in a report on Wednesday, April 30th.

Institutional Inflows and Outflows

A hedge fund recently bought a new stake in Surmodics stock. Strs Ohio purchased a new position in Surmodics, Inc. (NASDAQ:SRDX - Free Report) during the 1st quarter, according to its most recent 13F filing with the SEC. The firm purchased 4,000 shares of the company's stock, valued at approximately $122,000. Institutional investors and hedge funds own 96.63% of the company's stock.

About Surmodics

Surmodics, Inc, together with its subsidiaries, provides performance coating technologies for intravascular medical devices, and chemical and biological components for in vitro diagnostic immunoassay tests and microarrays in the United States and internationally. It operates through two segments, Medical Device and In Vitro Diagnostics (IVD).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.